First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

ApTOLL is an aptamer that antagonizes Toll-like receptor 4 and improves functional outcomes in models of ischemic stroke and myocardial infarction. The aim of this study was to characterize the safety and pharmacokinetics of ApTOLL in healthy volunteers. A first-in-human dose-ascending, randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Jiménez, Macarena, Martín-Vílchez, Samuel, Ochoa, Dolores, Mejía-Abril, Gina, Román, Manuel, Camargo-Mamani, Paola, Luquero-Bueno, Sergio, Jilma, Bernd, Moro, María A., Fernández, Gerónimo, Piñeiro, David, Ribó, Marc, González, Víctor M., Lizasoain, Ignacio, Abad-Santos, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938885/
https://www.ncbi.nlm.nih.gov/pubmed/35402075
http://dx.doi.org/10.1016/j.omtn.2022.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938885/
https://www.ncbi.nlm.nih.gov/pubmed/35402075
http://dx.doi.org/10.1016/j.omtn.2022.03.005

Ejemplares similares